Trials / Completed
CompletedNCT05152212
Study of LVGN7409 (CD40 Agonist Antibody) in Locally Advanced, Metastatic or Recurrent/Refractory Malignancy
An Open Label, Phase I Trial of LVGN7409 as Single Agent in Locally Advanced, Metastatic or Recurrent/Refractory Malignancy
- Status
- Completed
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 33 (actual)
- Sponsor
- Lyvgen Biopharma Holdings Limited · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
The study of LVGN7409-201 is designed to use a bridging dose escalation to quickly establish the maximum tolerated dose (MTD) and/or the recommended dose for expansion (RDE) as well as the recommended Phase 2 dose(s) (RP2D) of LVGN7409 as a single agent (monotherapy) in the treatment of locally advanced, metastatic or recurrent/refractory malignancy.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| BIOLOGICAL | LVGN7409 | Route of administration is IV infusion, and the frequency of administration is once every 3 weeks(Q3W). One cycle is 3 weeks, and treatment can be up to 35 cycles if patients receive benefits. |
Timeline
- Start date
- 2021-09-29
- Primary completion
- 2023-12-19
- Completion
- 2023-12-19
- First posted
- 2021-12-09
- Last updated
- 2024-04-22
Locations
1 site across 1 country: China
Source: ClinicalTrials.gov record NCT05152212. Inclusion in this directory is not an endorsement.